Logo image of BGMS

BIO GREEN MED SOLUTION INC (BGMS) Stock Fundamental Analysis

USA - NASDAQ:BGMS - US23254L8761 - Common Stock

5.15 USD
+0.41 (+8.65%)
Last: 9/26/2025, 8:00:02 PM
5.1 USD
-0.05 (-0.97%)
After Hours: 9/26/2025, 8:00:02 PM
Fundamental Rating

3

BGMS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 540 industry peers in the Biotechnology industry. The financial health of BGMS is average, but there are quite some concerns on its profitability. BGMS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BGMS has reported negative net income.
BGMS had a negative operating cash flow in the past year.
BGMS had negative earnings in each of the past 5 years.
In the past 5 years BGMS always reported negative operating cash flow.
BGMS Yearly Net Income VS EBIT VS OCF VS FCFBGMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of BGMS (-146.06%) is worse than 84.63% of its industry peers.
Looking at the Return On Equity, with a value of -177.03%, BGMS is doing worse than 64.63% of the companies in the same industry.
Industry RankSector Rank
ROA -146.06%
ROE -177.03%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BGMS Yearly ROA, ROE, ROICBGMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

BGMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGMS Yearly Profit, Operating, Gross MarginsBGMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for BGMS has been increased compared to 1 year ago.
BGMS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BGMS Yearly Shares OutstandingBGMS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
BGMS Yearly Total Debt VS Total AssetsBGMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -138.32, we must say that BGMS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -138.32, BGMS is doing worse than 97.04% of the companies in the same industry.
There is no outstanding debt for BGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -138.32
ROIC/WACCN/A
WACCN/A
BGMS Yearly LT Debt VS Equity VS FCFBGMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 5.77 indicates that BGMS has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.77, BGMS is doing good in the industry, outperforming 61.85% of the companies in the same industry.
A Quick Ratio of 5.77 indicates that BGMS has no problem at all paying its short term obligations.
BGMS has a Quick ratio of 5.77. This is in the better half of the industry: BGMS outperforms 62.04% of its industry peers.
Industry RankSector Rank
Current Ratio 5.77
Quick Ratio 5.77
BGMS Yearly Current Assets VS Current LiabilitesBGMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

BGMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.85%, which is quite impressive.
BGMS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.50%.
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 57.16% on average over the next years. This is a very strong growth
Based on estimates for the next years, BGMS will show a very strong growth in Revenue. The Revenue will grow by 1049.89% on average per year.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A

3.3 Evolution

BGMS Yearly Revenue VS EstimatesBGMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2023 2024 2025 2026 2027 20M 40M 60M 80M
BGMS Yearly EPS VS EstimatesBGMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10K -20K -30K -40K -50K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BGMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BGMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGMS Price Earnings VS Forward Price EarningsBGMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGMS Per share dataBGMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

BGMS's earnings are expected to grow with 57.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

More info and screens

0

5. Dividend

5.1 Amount

BGMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIO GREEN MED SOLUTION INC

NASDAQ:BGMS (9/26/2025, 8:00:02 PM)

After market: 5.1 -0.05 (-0.97%)

5.15

+0.41 (+8.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12
Earnings (Next)11-10 2025-11-10
Inst Owners1.06%
Inst Owner ChangeN/A
Ins Owners63.57%
Ins Owner Change0%
Market Cap11.54M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-37.21%
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-50.98%
Min Revenue beat(4)-100%
Max Revenue beat(4)96.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1153.6
P/FCF N/A
P/OCF N/A
P/B 3.18
P/tB 3.18
EV/EBITDA N/A
EPS(TTM)-122.02
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-3.9
FCFYN/A
OCF(TTM)-3.9
OCFYN/A
SpS0
BVpS1.62
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -146.06%
ROE -177.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.77
Quick Ratio 5.77
Altman-Z -138.32
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A
EBIT growth 1Y48.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.04%
OCF growth 3YN/A
OCF growth 5YN/A